Affinity Asset Advisors LLC Has $9.81 Million Holdings in Rezolute, Inc. $RZLT

Affinity Asset Advisors LLC grew its holdings in Rezolute, Inc. (NASDAQ:RZLT) by 29.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,200,000 shares of the company’s stock after acquiring an additional 500,000 shares during the quarter. Rezolute accounts for 1.3% of Affinity Asset Advisors LLC’s portfolio, making the stock its 23rd largest holding. Affinity Asset Advisors LLC owned approximately 2.53% of Rezolute worth $9,812,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Marshall Wace LLP raised its stake in Rezolute by 56.4% during the 2nd quarter. Marshall Wace LLP now owns 2,886,481 shares of the company’s stock valued at $12,874,000 after purchasing an additional 1,041,234 shares during the last quarter. Decheng Capital LLC acquired a new stake in Rezolute in the 2nd quarter worth $267,000. Stonepine Capital Management LLC bought a new position in shares of Rezolute during the 2nd quarter worth about $977,000. Invesco Ltd. bought a new position in shares of Rezolute during the 2nd quarter worth about $172,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Rezolute during the second quarter valued at about $104,000. Institutional investors and hedge funds own 82.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group reissued a “buy” rating and set a $20.00 target price on shares of Rezolute in a research report on Friday. JMP Securities set a $17.00 price objective on Rezolute in a research report on Wednesday, October 29th. BTIG Research reissued a “buy” rating and set a $17.00 price objective on shares of Rezolute in a report on Thursday, November 20th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research note on Wednesday, September 3rd. Finally, Wall Street Zen raised Rezolute from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.50.

Rezolute Stock Performance

Shares of NASDAQ:RZLT opened at $10.42 on Friday. Rezolute, Inc. has a 52 week low of $2.21 and a 52 week high of $11.46. The company’s fifty day moving average is $9.39 and its 200-day moving average is $7.04. The company has a market capitalization of $966.25 million, a PE ratio of -11.20 and a beta of 0.21.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.09. On average, analysts forecast that Rezolute, Inc. will post -0.93 EPS for the current year.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.